{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:56:19Z","timestamp":1781232979887,"version":"3.54.1"},"reference-count":37,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Precision medicine in prostate cancer (PCa) is increasingly best understood as a continuum linking risk-adapted detection, multimodal diagnosis and phenotyping, and implementation-ready decision pathways. Contemporary clinical guidelines emphasize structured diagnostic strategies, appropriate use of advanced imaging, and selective deployment of biomarkers when results can alter management. Upstream risk enrichment using polygenic risk scores and multivariable prediction models may improve the yield of clinically significant disease while mitigating harms related to overdiagnosis. At the point of suspicion, magnetic resonance imaging-first pathways and reflex biomarker testing provide practical tools to reduce unnecessary biopsy while maintaining safeguards for the detection of clinically important disease. Beyond diagnosis, prostate-specific membrane antigen positron emission tomography refines disease-state phenotyping in initial staging, biochemical recurrence, and limited-burden presentations, while standardized acquisition and reporting improve reproducibility and multidisciplinary communication. Germline and tumor-based molecular profiling should be operationalized as a longitudinal care process with clear consent, turnaround targets, and test-to-action rules that define what each result enables at specific decision nodes. Finally, longitudinal monitoring approaches, including liquid biopsy and artificial intelligence-enabled pathology, are evolving rapidly and require transparent reporting and rigorous risk-of-bias appraisal before broad clinical adoption. This narrative review synthesizes key evidence across the precision continuum and outlines a decision-node-based, test-to-action framework for maximizing clinical benefit, maintaining quality, and ensuring equitable access.<\/jats:p>","DOI":"10.3390\/cancers18121909","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:52:08Z","timestamp":1781229128000},"page":"1909","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Precision Diagnostics and Personalized Therapeutics for Prostate Cancer: An Integrated Precision Continuum from Risk-Adapted Detection to Biomarker-Directed Therapy and Dynamic Monitoring"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7869-2742","authenticated-orcid":false,"given":"Takahide","family":"Noro","sequence":"first","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-7361","authenticated-orcid":false,"given":"Takanobu","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"},{"name":"Department of Urology, Toho University Graduate School of Medicine, Tokyo 143-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuharu","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Graduate School of Medicine, Tokyo 143-8540, Japan"},{"name":"Department of Urology, Seirei Sakura Citizen Hospital, Sakura 285-8765, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"},{"name":"Department of Urology, Toho University Graduate School of Medicine, Tokyo 143-8540, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodai","family":"Kadono","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Graduate School of Medicine, Tokyo 143-8540, Japan"},{"name":"Department of Urology, Mihama Hospital, Chiba 261-0013, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugizaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Somoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-2490","authenticated-orcid":false,"given":"Naoto","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5838-114X","authenticated-orcid":false,"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center, Sakura 285-8741, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part II: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_5","unstructured":"American Urological Association, and Society of Urologic Oncology (2026, May 06). Early Detection of Prostate Cancer: AUA\/SUO Guideline (Updated through the AUA Amendment Process, 2025). Available online: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/early-detection-of-prostate-cancer-guideline."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a Polygenic Risk Score in Screening for Prostate Cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ajhg.2023.05.010","article-title":"Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry","volume":"110","author":"Darst","year":"2023","journal-title":"Am. J. Hum. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-Based, Randomised, Open-Label, Non-Inferiority Trial","volume":"22","author":"Discacciati","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-Targeted or Standard Biopsy in Prostate Cancer Screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after Four Years of Screening for Prostate Cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41391-020-0237-z","article-title":"Clinical Utility of the Exosome-Based ExoDx Prostate (IntelliScore) EPI Test in Men Presenting for Initial Biopsy with a PSA 2\u201310 ng\/mL","volume":"23","author":"Tutrone","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1038\/s41598-022-08608-z","article-title":"Validation of a CE-IVD, Urine Exosomal RNA Expression Assay for Risk Assessment of Prostate Cancer Prior to Biopsy","volume":"12","author":"Kretschmer","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00028","DOI":"10.1097\/JU9.0000000000000134","article-title":"The Clinical Impact of the 4Kscore Test on Prostate Biopsy Decision Making in the Setting of MRI","volume":"2","author":"Wang","year":"2024","journal-title":"JU Open Plus"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wu, H., Wu, Y., He, P., Liang, J., Xu, X., and Ji, C. (2024). A Meta-Analysis for the Diagnostic Accuracy of SelectMDx in Prostate Cancer. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0285745"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic Performance of 18F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM Procedure Guideline\/SNMMI Procedure Standard for Prostate Cancer Imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Oka, R., Utsumi, T., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., Somoto, T., Kato, S., Endo, T., and Kamiya, N. (2024). Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches. Cancers, 16.","DOI":"10.3390\/cancers16030507"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Somoto, T., Utsumi, T., Ikeda, R., Ishitsuka, N., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., Oka, R., and Endo, T. (2025). Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32120698"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kopytov, S.A., Sagitova, G.R., Guschin, D.Y., Egorova, V.S., Zvyagin, A.V., and Rzhevskiy, A.S. (2025). Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management. Cancers, 17.","DOI":"10.3390\/cancers17152589"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/PO.20.00200","article-title":"Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer","volume":"4","author":"Armstrong","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1200\/JCO.24.00365","article-title":"Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men with High-Risk Prostate Cancer across Multiple Phase III Trials","volume":"43","author":"Armstrong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.landig.2025.100885","article-title":"External Validation of a Digital Pathology-Based Multimodal Artificial Intelligence-Derived Prognostic Model in Patients with Advanced Prostate Cancer Starting Long-Term Androgen Deprivation Therapy: A Post Hoc Ancillary Biomarker Study of Four Phase 3 Randomised Controlled Trials of the STAMPEDE Platform Protocol","volume":"7","author":"Parker","year":"2025","journal-title":"Lancet Digit. Health"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI Statement: Updated Guidance for Reporting Clinical Prediction Models that Use Regression or Machine Learning Methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: An Updated Quality, Risk of Bias, and Applicability Assessment Tool for Prediction Models Using Regression or Artificial Intelligence Methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part II: Treatment Delivery for Non-Metastatic Biochemical Recurrence after Primary Radical Prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1909\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:01:56Z","timestamp":1781229716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121909"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121909","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}